Rhythm Eyes Bigger Market For Imcivree Following Phase II Hypothalamic Obesity Promise
The US firm’s Imcivree has impressed with interim mid-stage data from a hypothalamic obesity study, paving the way for pivotal success that could open up a much larger market.
You may also be interested in...
France is set to become the first country in Europe to fund Imcivree for a second – and as yet unapproved – indication. Meanwhile, England has agreed to reimburse the drug for its approved indication as did Germany earlier this year. Reimbursement discussions are underway in the rest of Europe.
The company got FDA approval for the drug in Bardet-Biedl syndrome, on top of the existing approval from November 2020 in obesity due to POMC, PCSK1 and LEPR deficiency.
The major will use the biotech’s brain cell-focused platform technology to discover new targets for Alzheimer’s disease.